Efficacy and prognostic factors in children with non-core binding factor acute myeloid leukemia
CHEN Xiao-Yan, LIU Chao, WU Wen-Qi, ZHANG Ao-Li, LIU Li-Peng, LAN Yang, CAI Yu-Li, RUAN Min, ZHU Xiao-Fan
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
目的 回顾性分析比较非核心结合因子（CBF）急性髓系白血病（AML）儿童采用CAMS-2005方案及CAMS-2009方案治疗的疗效及预后的影响因素。方法 选择2005年4月至2015年12月161例初诊为非CBF-AML患儿为研究对象，根据化疗方案分为CAMS-2005方案组（n=52）和CAMS-2009方案组（n=109），对两种化疗方案疗效进行回顾性分析。结果 CAMS-2009方案组第1个疗程完全缓解率高于CAMS-2005方案组（63.3% vs 46.2%，P < 0.05）。CAMS-2009方案组治疗相关病死率（11.9% vs 17.3%）、复发率（27.5% vs 28.8%）、3年总生存（OS）率（44%±5% vs 28%±6%）与CAMS-2005方案组相比差异无统计学意义（P > 0.05）。第1个疗程获得完全缓解患儿的3年OS率、3年无事件生存率高于第1个疗程未完全缓解患儿（P < 0.01）。结论 CAMS-2009方案较CAMS-2005方案可改善非CBF-AML患儿诱导治疗完全缓解率，第1个疗程是否获完全缓解可影响非CBF-AML患儿OS率。
Abstract：Objective To compare the efficacy of the CAMS-2005 and CAMS-2009 regimens in treating children with non-core binding factor acute myeloid leukemia (non-CBF AML) and to study the prognosis factors. Methods A total of 161 children who were initially diagnosed with non-CBF AML from April 2005 to December 2015 were enrolled as study subjects, and were divided into a CAMS-2005 regimen group (n=52) and a CAMS-2009 regimen group (n=109) according to the chemotherapy regimen provided. The efficacy was retrospectively compared between the two groups. Results The complete remission (CR) rate at the first course of treatment was higher in the CAMS-2009 regimen group than that in the CMAS-2005 regimen group (63.3% vs 46.2%; P < 0.05). There were no significant differences between the two groups in treatment-related mortality rate (11.9% vs 17.3%), recurrence rate (27.5% vs 28.8%), and three-year overall survival (OS) rate (44%±5% vs 28%±6%) (P > 0.05). Children who achieved CR at the first course of treatment had significantly higher OS and event-free survival rates than those who did not achieved CR (P < 0.01). Conclusions The CAMS-2009 regimen is superior to the CAMS-2005 regimen in improving the CR rate in children with non-CBF AML after induction treatment. Whether CR is achieved at the first course of treatment can affect the OS rate of children with non-CBF AML.
CHEN Xiao-Yan,LIU Chao,WU Wen-Qi et al. Efficacy and prognostic factors in children with non-core binding factor acute myeloid leukemia[J]. CJCP, 2020, 22(5): 466-472.
Taga T, Tomizawa D, Takahashi H, et al. Acute myeloid leukemia in children:current status and future directions[J].Pediatr Int, 2016, 58(2):71-80.
[2]
Klein K, de Haas V, Kaspers GJL. Clinical challenges in de novo pediatric acute myeloid leukemia[J]. Expert Rev Anticancer Ther, 2018, 18(3):277-293.
[3]
Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia[J]. J Clin Oncol, 2015, 33(27):2949-2962.
[4]
Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia:a retrospective analysis of the AML-BFM trials from 1987 to 2012[J]. Leukemia, 2018, 32(10):2167-2177.
[5]
Faber ZJ, Chen X, Gedman AL, et al. The genomic landscape of core-binding factor acute myeloid leukemias[J]. Nat Genet, 2016, 48(12):1551-1556.
[6]
von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98[J]. J Clin Oncol, 2010, 28(16):2682-2689.
[7]
Paschka P, Schlenk RF, Weber D, et al. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial[J]. Leukemia, 2018, 32(7):1621-1630.
[8]
Selim AG, Moore AS. Molecular minimal residual disease monitoring in acute myeloid leukemia:challenges and future directions[J]. J Mol Diagn, 2018, 20(4):389-397.
[9]
Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia:the AML99 trial from the Japanese Childhood AML Cooperative Study Group[J]. J Clin Oncol, 2009, 27(24):4007-4013.
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group[J]. Br J Haematol, 1976, 33(4):451-458.
[13]
Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia:results of the medical research council AML15 trial[J]. J Clin Oncol, 2013, 31(27):3360-3368.
[14]
Shimada N, Ohno N, Tanosaki R, et al. Therapy-related acute myeloid leukemia after the long-term administration of low-dose etoposide for vhronic-type adult T-cell leukemia-lymphoma:a case report and literature review[J]. Intern Med, 2017, 56(14):1879-1884.
[15]
Pan H, Feng DN, Song L, et al. Acute myeloid leukemia following etoposide therapy for EBV-associated hemophagocytic lymphohistiocytosis:a case report and a brief review of the literature[J]. BMC Pediatr, 2016, 16:116.
[16]
Pendleton M, Lindsey RH Jr, Felix CA, et al. Topoisomerase II and leukemia[J]. Ann N Y Acad Sci, 2014, 1310:98-110.
[17]
de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML:from biology to clinical management[J]. J Clin Med, 2015, 4(1):127-149.
[18]
Suh JK, Lee SW, Koh KN, et al. Hematopoietic stem cell transplantation in pediatric patients with acute myeloid leukemia without favorable cytogenetics[J]. Pediatr Transplant, 2017. DOI:10.1111/petr.13004. Epub 2017 Aug 1.
[19]
Hyakuna N, Hashii Y, Ishida H, et al. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial[J]. Pediatr Blood Cancer, 2019, 66(10):e27875.
[20]
van Eijkelenburg NKA, Rasche M, Ghazaly E, et al. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia:a phase IB study[J]. Haematologica, 2018, 103(9):1484-1492.
[21]
Hochberg J, Zahler S, Geyer MB, et al. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia[J]. Bone Marrow Transplant, 2019, 54(2):226-235.
[22]
Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk:results from the randomized phase III Children's Oncology Group trial AAML0531[J]. J Clin Oncol, 2014, 32(27):3021-3032.
[23]
Niktoreh N, Lerius B, Zimmermann M, et al. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia:a report by Berlin-Frankfurt-Münster study group[J].Haematologica, 2019, 104(1):120-127.
[24]
Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia:medical research council AML12 trial[J]. Br J Haematol, 2011, 155(3):366-376.
[25]
Sung L, Aplenc R, Alonzo TA, et al. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia:a report from the Children's Oncology Group[J].Haematologica, 2012, 97(11):1770-1773.
[26]
Betts DR, Ammann RA, Hirt A, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)[J]. Eur J Haematol, 2007, 78(6):468-476.
[27]
Sander A, Zimmermann M, Dworzak M, et al. Consequent and intensified relapse therapy improved survival in pediatric AML:results of relapse treatment in 379 patients of three consecutive AML-BFM trials[J]. Leukemia, 2010, 24(8):1422-1428.
